Quote this publication Share Print


Opinions on drugs - Posted on Feb 06 2013

Reason for request

Inclusion on the list of medicines reimbursed by National Insurance (packs of 28) and on the list of medicines approved for use by hospitals and various public services (packs of 28 and 100).


Clinical Benefit


The actual benefit of VALDOXAN in the treatment of major depressive episodes is substantial.

Clinical Added Value


Given the good safety likely to improve compliance to antidepressive treatment and despite its modest efficacy, VALDOXAN provides a minor improvement to actual benefit (IAB IV) in the management of major depressive episodes (characteristic symptoms).

Contact Us

Évaluation des médicaments

See also